Coronary heart disease mortality and adjuvant tamoxifen therapy

Journal of the National Cancer Institute

Volumn 89, Issue 11, 1997, Pages 776-782

  Costantino, Joseph P ^a   Kuller, Lewis H ^a   Ives, Diane G ^a   Fisher, Bernard ^b,c   Dignam, James ^d  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Natl Surg Adjuvant Breast/Bowel P   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORONARY RISK; CORRELATION FUNCTION; DRUG EFFICACY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY;

EID: 0030941737     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.11.776     Document Type: Article

References (23)

1. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
2. Fisher B, Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr 1992;11:105-16.
3. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
4. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991;303:435-7.
5. McDonald CC, Alexander FE, Whytc BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995;311:977-80.
6. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-406.
7. Kuller LH, Shemanski L, Psaty BM, Borhani NO, Gardin J, Haan MN, et al. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation 1995;92:720-6.
8. Rosner B. Fundamentals of biostatistics. 4th ed. Belmont (CA): Wadsworth Publishing Company, 1993:588-94.
9. Korn EL, Dorey FJ. Applications of crude incidence curves. Stat Med 1992;11:813-29.
10. Bagdade JD, Wolter J, Subbaiah PV, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 1990;70:1132-5.
11. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988;12:307-10.
12. Bruning PF, Bonfrer JM, Hart AA, de Jong-Bakker M, Linders D, van Loon J, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988;58:497-9.
13. Cuzick J. Allen D. Baum M, Barrett J, Clark G, Kakkar V, et al. Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. Eur J Cancer 1993;29A:15-21.
14. Ingram D. Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer. Aust N Z J Surg 1990;60:673-5.
15. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1327-32.
16. Powles TJ, Tillyer CR, Jones AL, Ashely SE, Treleaven J, Davey JB, et al. Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990;26:680-4.
17. Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984;52:339-46.
18. Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RA. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 1992;305:225-6.
19. Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks? Nat Med 1996;2:381-5.
20. Williams JK, Adams MR. The estrogen receptor agonist/antagonist tamoxifen inhibits progression of coronary artery atherosclerosis in monkeys. Circulation 1995;92(suppl 1):627.
21. Wiseman H, Paganga G, Rice-Evans C, Halliwell B. Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of lamoxifen? Biochem J 1993;292(Pt 3):635-8.
22. Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO 3rd. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol 1995;76:1072-3.
23. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94.